Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab + nivolumab fixed-dose combination with chemotherapy versus placebo + chemotherapy in first-line LAG-3-positive gastric or gastroesophageal junction adenocarcinoma
2017-004896-30Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of relatlimab and nivolumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Overall survival. Started Apr 2018; status: terminated.
02
Drugs
relatlimabnivolumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2017-004896-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004896-30.